Zephyr AI Closes $111 Million in Series A

Zephyr AI Closes $111 Million in Series A

Zephyr AI, a McLean, Virginia-based healthcare technology company committed to developing fast and explainable AI solutions to democratize precision medicine, closed a $111 million Series A funding round.

Revolution Growth, Eli Lilly & Company, Jeff Skoll, and EPIQ Capital Group participated in the funding.

The company will use the funds to accelerate the development of its AI solutions in precision medicine, focusing on oncology and cardiometabolic disease. The company aims to enhance data federation tools and machine learning algorithms.

Founded in 2020, Zephyr AI is a high-growth healthcare technology company developing improved data federation tools along with various machine learning algorithms in the areas of oncology and cardiometabolic disease. The company utilizes large, complex data and proprietary algorithms to redefine drug development, streamline clinical trials, battle diseases, and provide clinical decision support. Through partnerships and proprietary data, Zephyr AI is curating the world’s most comprehensive healthcare dataset and merging it with cutting-edge artificial intelligence algorithms to generate novel, translatable insights. These insights are used to build tools and products that support patients and providers, as well as to fuel ongoing research.

Funding Details

Company: Zephyr AI, Inc.

Raised: $111.0M

Round: Series A

Funding Month: March 2024

Investors: Revolution Growth, Eli Lilly & Company, Jeff Skoll, and EPIQ Capital Group

Company Website: https://www.zephyrai.bio/

Software Category: AI Drug Development and Precision Medicine